Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression

Efficacy and Safety of Aripiprazole 2.5mg Combine Sertraline 50mg in Major Depression

FDA has accepted atypical antipsychotics of olanzapine and aripiprazole as the adjuvant medications for refractory major depression. But there is still no trial about atypical antipsychotics combined with antidepressant of SSRI used in fresh major depressive patients. This project aims to compare the efficacy and tolerability of sertraline with or without low-dosed aripiprazole added in fresh major depression.

Study Overview

• Status: Completed
• Conditions: Major Depressive Disorder
• Intervention / Treatment: Drug: aripiprazole , sertraline

Detailed Description

This double-blind, placebo-control, fixed dose, randomized study will be conducted at a tertiary clinical setting. Patients over 18 y/o fulfilled DSM-IV criteria for major depression, having a baseline HAM-D score ≧ 14 and a HAM-D item 3 score < 3 will be recruited into the groups. The study group of patients will receive ten weeks of treatment with a combination of fix-dosed sertraline and aripiprazole. The control group will received sertraline only. The score reduction in HAM-D17, CGI, SF-36 and Brief Symptom Rating Scale (BSRS-50) will be periodically estimated as an efficacy following the use of a SSRIs or and aripiprazole.

• Study Type: Interventional
• Enrollment (Actual): 41
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Taiwan
  • Tainan, Taiwan, 700
    • Psychiatry Department, Chimei Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female subjects 18 to 65 years inclusive.
• Fulfilled DSM-Ⅳ criteria for major depressive disorder.
• Onset ≧2 weeks.
• Baseline score ≧14 on the HAM-D17.
• Written informed consent prior to entry into the study.

Exclusion Criteria:

• HAM-D17 item 3 score≧3.
• Life-time history of bipolar disorders, schizophrenia or schizoaffective disorder.
• Current history of panic disorder, obsessive-compulsive disorder, alcohol or substance abuse.
• Mood disorder due to general medical condition.
• Treatment with antidepressants at entry into the study before 2 weeks.
• Need for psychoactive medications other than the study drugs, except for one benzodiazepine or hypnotic given at a stable dose.
• Known intolerance or inefficacy to either drug.
• Previous lack of response to two or more antidepressants at adequate dosage.
• Subjects who have acute or unstable medical illness or organic failure.
• Pregnancy and breast-feeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: aripiprazole and sertraline; The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and aripiprazole 2.5mg/day.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.	Drug: aripiprazole , sertraline; In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
Placebo Comparator: sertraline and placebo; The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and placebo.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.	Drug: aripiprazole , sertraline; In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
score change of Hamilton Rating Scale For Depression (HAM-D17 )	day 1 / 1 week / 2 weeks/ 4 weeks/ 6 weeks/ 10weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
score change of Brief Psychiatric Rating Scale (BPRS-50)	day 1/ 1 week / 2 weeks/ 4 weeks/ 6 weeks/ 10 weeks

Collaborators and Investigators

• Sponsor: Chimei Medical Center

Study record dates

Study Major Dates

• Study Start: April 1, 2007
• Primary Completion (Actual): March 1, 2009
• Study Completion (Actual): March 1, 2009

Study Registration Dates

• First Submitted: March 31, 2009
• First Submitted That Met QC Criteria: April 1, 2009
• First Posted (Estimate): April 2, 2009

Study Record Updates

• Last Update Posted (Estimate): April 2, 2009
• Last Update Submitted That Met QC Criteria: April 1, 2009
• Last Verified: April 1, 2009

More Information

Terms related to this study

• Keywords: tolerability; efficacy; combination of aripiprazole and SSRI(sertraline)
• Additional Relevant MeSH Terms: Mental Disorders; Mood Disorders; Depressive Disorder; Depressive Disorder, Major; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Antipsychotic Agents; Tranquilizing Agents; Psychotropic Drugs; Serotonin Uptake Inhibitors; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Serotonin Agents; Antidepressive Agents; Dopamine Agonists; Dopamine Agents; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Dopamine D2 Receptor Antagonists; Dopamine Antagonists; Aripiprazole; Sertraline
• Other Study ID Numbers: IRB 09603-001